Published in PLoS Negl Trop Dis on July 13, 2010
The Trypanosoma cruzi flagellum is discarded via asymmetric cell division following invasion and provides early targets for protective CD8⁺ T cells. Cell Host Microbe (2014) 1.48
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nat Rev Microbiol (2017) 1.38
New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J Infect Dis (2013) 1.23
Activity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screening. PLoS Negl Trop Dis (2011) 1.15
Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. Cell Microbiol (2014) 1.14
Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge. Infect Immun (2011) 0.94
Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents. J Med Chem (2011) 0.93
Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents. Bioorg Med Chem (2013) 0.92
Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs. Antimicrob Agents Chemother (2015) 0.92
In vivo imaging of mice infected with bioluminescent Trypanosoma cruzi unveils novel sites of infection. Parasit Vectors (2014) 0.89
Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents. J Med Chem (2012) 0.89
Evidence for the role of vacuolar soluble pyrophosphatase and inorganic polyphosphate in Trypanosoma cruzi persistence. Mol Microbiol (2013) 0.89
Bioluminescent imaging of Trypanosoma cruzi infection in Rhodnius prolixus. Parasit Vectors (2012) 0.88
Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies. Future Med Chem (2013) 0.88
Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity. Mem Inst Oswaldo Cruz (2014) 0.88
Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase. Bioorg Med Chem (2011) 0.88
Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents. Eur J Med Chem (2012) 0.87
Risedronate metal complexes potentially active against Chagas disease. J Inorg Biochem (2010) 0.87
A new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imaging. J Biomol Screen (2014) 0.85
Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line. PLoS Negl Trop Dis (2015) 0.84
1-(Fluoroalkylidene)-1,1-bisphosphonic acids are potent and selective inhibitors of the enzymatic activity of Toxoplasma gondii farnesyl pyrophosphate synthase. Org Biomol Chem (2012) 0.84
Translational challenges of animal models in Chagas disease drug development: a review. Drug Des Devel Ther (2015) 0.83
Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade. PLoS Negl Trop Dis (2016) 0.83
Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives. Mem Inst Oswaldo Cruz (2015) 0.82
Stage-regulated GFP Expression in Trypanosoma cruzi: applications from host-parasite interactions to drug screening. PLoS One (2013) 0.80
Transgenic parasites accelerate drug discovery. Trends Parasitol (2012) 0.80
Design, synthesis and biological evaluation of WC-9 analogs as antiparasitic agents. Eur J Med Chem (2013) 0.80
Luminescent multiplex viability assay for Trypanosoma brucei gambiense. Parasit Vectors (2013) 0.80
Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge. PLoS Negl Trop Dis (2011) 0.80
High throughput screening for anti-Trypanosoma cruzi drug discovery. PLoS Negl Trop Dis (2014) 0.79
Genetically attenuated Trypanosoma cruzi parasites as a potential vaccination tool. Bioengineered (2012) 0.79
Aryloxyethyl Thiocyanates Are Potent Growth Inhibitors of Trypanosoma cruzi and Toxoplasma gondii. ChemMedChem (2015) 0.78
Putting Infection Dynamics at the Heart of Chagas Disease. Trends Parasitol (2016) 0.77
Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage. Sci Rep (2016) 0.76
Reaching for the Holy Grail: insights from infection/cure models on the prospects for vaccines for Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz (2015) 0.76
The in vitro activity of fatty diamines and amino alcohols against mixed amastigote and trypomastigote Trypanosoma cruzi forms. Mem Inst Oswaldo Cruz (2014) 0.76
New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase. Bioorg Med Chem (2013) 0.75
Next-generation antimicrobials: from chemical biology to first-in-class drugs. Arch Pharm Res (2015) 0.75
Activity of Fluorine-Containing Analogues of WC-9 and Structurally Related Analogues against Two Intracellular Parasites: Trypanosoma cruzi and Toxoplasma gondii. ChemMedChem (2016) 0.75
Identification and Characterization of the Trypanosoma cruzi B-cell Superantigen Tc24. Am J Trop Med Hyg (2015) 0.75
Natural terpenoids from Ambrosia species are active in vitro and in vivo against human pathogenic trypanosomatids. PLoS Negl Trop Dis (2013) 0.75
Trypanocidal Activity of Smallanthus sonchifolius: Identification of Active Sesquiterpene Lactones by Bioassay-Guided Fractionation. Evid Based Complement Alternat Med (2013) 0.75
Evaluation of Parameters Impacting Drug Susceptibility in Intracellular Trypanosoma cruzi Assay Protocols. J Biomol Screen (2016) 0.75
Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol (2004) 36.25
Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA (2007) 5.22
The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop (1997) 4.73
The future of Chagas disease control. Trends Parasitol (2006) 4.65
Control of Chagas disease. World Health Organ Tech Rep Ser (2002) 4.00
A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz (2002) 3.84
Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis (2007) 3.80
Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother (1996) 3.62
Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol (2003) 2.93
The challenges of Chagas Disease-- grim outlook or glimmer of hope. PLoS Med (2007) 2.79
Dynamics of neutrophil migration in lymph nodes during infection. Immunity (2008) 2.70
Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med (1998) 2.45
Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop (2009) 2.37
Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med (2008) 2.04
Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther (2009) 1.99
Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother (2000) 1.87
Phenotypic screening of small molecule libraries by high throughput cell imaging. Comb Chem High Throughput Screen (2003) 1.70
Exo1: a new chemical inhibitor of the exocytic pathway. Proc Natl Acad Sci U S A (2003) 1.55
Far-red fluorescent tag for protein labelling. Biochem J (2002) 1.50
Functional analysis of the intergenic regions of TcP2beta gene loci allowed the construction of an improved Trypanosoma cruzi expression vector. Gene (1999) 1.50
Noninvasive optical tracking of red fluorescent protein-expressing cancer cells in a model of metastatic breast cancer. Neoplasia (2006) 1.45
Retrograde transport of cholera toxin from the plasma membrane to the endoplasmic reticulum requires the trans-Golgi network but not the Golgi apparatus in Exo2-treated cells. EMBO Rep (2004) 1.28
Bioluminescent imaging of Trypanosoma cruzi infection. Int J Parasitol (2008) 1.23
A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J Antimicrob Chemother (2000) 1.23
Integration of expression vectors into the ribosomal locus of Trypanosoma cruzi. Gene (2003) 1.16
Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening. PLoS Negl Trop Dis (2009) 1.09
In vitro and in vivo activity of lignan lactones derivatives against Trypanosoma cruzi. Parasitol Res (2006) 1.09
Expression of exogenous genes in Trypanosoma cruzi: improving vectors and electroporation protocols. Parasitol Res (2003) 1.08
Evaluation of high efficiency gene knockout strategies for Trypanosoma cruzi. BMC Microbiol (2009) 1.07
Eliminating Chagas disease: challenges and a roadmap. BMJ (2009) 1.06
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob Agents Chemother (2007) 1.05
Expression of fluorescent genes in Trypanosoma cruzi and Trypanosoma rangeli (Kinetoplastida: Trypanosomatidae): its application to parasite-vector biology. J Med Entomol (2005) 0.99
Setting of a colorimetric method to determine the viability of Trypanosoma cruzi epimastigotes. Parasitol Res (2000) 0.99
Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes. Parasitol Res (2006) 0.98
Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure. J Infect Dis (2002) 0.97
Cell culture and animal infection with distinct Trypanosoma cruzi strains expressing red and green fluorescent proteins. Int J Parasitol (2007) 0.95
Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening. Bioorg Med Chem Lett (2008) 0.92
Biological characterization of Trypanosoma cruzi strains. Mem Inst Oswaldo Cruz (2001) 0.90
Flagellar elongation induced by glucose limitation is preadaptive for Trypanosoma cruzi differentiation. Cell Motil Cytoskeleton (2000) 0.89
A method to assess invasion and intracellular replication of Trypanosoma cruzi based on differential uracil incorporation. J Immunol Methods (1998) 0.89
Natural chromenes and chromene derivatives as potential anti-trypanosomal agents. Biol Pharm Bull (2008) 0.87
A new pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing beta-galactosidase. Parasitol Res (2005) 0.86
Localization of lectin-binding sites on the surface of Trypanosoma cruzi grown in chemically defined conditions. Histochem Cell Biol (1998) 0.85
Synthesis and antiparasitic properties of new 4-N-benzylamino-4-hetarylbut-1-enes. Arch Pharm (Weinheim) (2005) 0.84
Synthesis and antiprotozoan properties of new 3,5-disubstituted-tetrahydro-2H-1,3,5-thiadiazine-2-thione derivatives. Arzneimittelforschung (1999) 0.81
In vitro activity of compounds isolated from Piper crassinervium against Trypanosoma cruzi. Nat Prod Res (2008) 0.80
Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines. Bioorg Med Chem (2010) 0.77
Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology (2011) 3.05
A Heuristic method for assigning a false-discovery rate for protein identifications from Mascot database search results. Mol Cell Proteomics (2005) 2.52
PCNA ubiquitination and REV1 define temporally distinct mechanisms for controlling translesion synthesis in the avian cell line DT40. Mol Cell (2008) 2.29
Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci (2012) 2.19
Deubiquitination of FANCD2 is required for DNA crosslink repair. Mol Cell (2007) 2.11
Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med (2008) 2.04
Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem (2005) 1.94
FISST based method for multi-target tracking in the image plane of optical sensors. Sensors (Basel) (2012) 1.93
CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog (2006) 1.93
Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol Biochem Parasitol (2003) 1.88
Epigenetic instability due to defective replication of structured DNA. Mol Cell (2010) 1.86
Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis (2004) 1.79
Drosophila neuropeptide F and its receptor, NPFR1, define a signaling pathway that acutely modulates alcohol sensitivity. Proc Natl Acad Sci U S A (2005) 1.78
Genome-wide analysis reveals Sall4 to be a major regulator of pluripotency in murine-embryonic stem cells. Proc Natl Acad Sci U S A (2008) 1.75
Microfluidic single-cell analysis shows that porcine induced pluripotent stem cell-derived endothelial cells improve myocardial function by paracrine activation. Circ Res (2012) 1.74
Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis (2012) 1.65
Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis (2009) 1.62
SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood (2008) 1.61
Vertebrate DNA damage tolerance requires the C-terminus but not BRCT or transferase domains of REV1. Nucleic Acids Res (2005) 1.56
Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. Hepatology (2014) 1.55
Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. Int Immunol (2006) 1.51
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis (2008) 1.46
Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun (2002) 1.45
Chromosome level assembly of the hybrid Trypanosoma cruzi genome. BMC Genomics (2009) 1.42
Potential new clinical therapies for Chagas disease. Expert Rev Clin Pharmacol (2014) 1.42
Oxygen electrocatalysts in metal-air batteries: from aqueous to nonaqueous electrolytes. Chem Soc Rev (2014) 1.37
CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol (2009) 1.36
Fast large-tip-angle multidimensional and parallel RF pulse design in MRI. IEEE Trans Med Imaging (2009) 1.34
The steady-state transcriptome of the four major life-cycle stages of Trypanosoma cruzi. BMC Genomics (2009) 1.33
Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection. J Immunol (2005) 1.33
Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol (2008) 1.23
New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J Infect Dis (2013) 1.23
Role for RAD18 in homologous recombination in DT40 cells. Mol Cell Biol (2006) 1.19
HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease. PLoS Negl Trop Dis (2008) 1.19
Interleukin-4 production by follicular helper T cells requires the conserved Il4 enhancer hypersensitivity site V. Immunity (2012) 1.19
Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection. J Immunol (2009) 1.17
MicroRNA-134 plasma levels before and after treatment for bipolar mania. J Psychiatr Res (2010) 1.17
Joint design of spoke trajectories and RF pulses for parallel excitation. Magn Reson Med (2010) 1.16
ZIF-8 derived graphene-based nitrogen-doped porous carbon sheets as highly efficient and durable oxygen reduction electrocatalysts. Angew Chem Int Ed Engl (2014) 1.13
Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence. J Immunol (2009) 1.12
Differences in osteogenic differentiation of adipose-derived stromal cells from murine, canine, and human sources in vitro and in vivo. Plast Reconstr Surg (2011) 1.10
Multilocus enzyme electrophoresis analysis of Trypanosoma cruzi isolates from a geographically restricted endemic area for Chagas' disease in Argentina. Int J Parasitol (2003) 1.10
Widespread, focal copy number variations (CNV) and whole chromosome aneuploidies in Trypanosoma cruzi strains revealed by array comparative genomic hybridization. BMC Genomics (2011) 1.09
Evaluation of high efficiency gene knockout strategies for Trypanosoma cruzi. BMC Microbiol (2009) 1.07
Blockade of store-operated Ca(2+) entry inhibits hepatocarcinoma cell migration and invasion by regulating focal adhesion turnover. Cancer Lett (2012) 1.06
Monochromatic wavefront aberrations in the human eye with contact lenses. Optom Vis Sci (2003) 1.06
Eliminating Chagas disease: challenges and a roadmap. BMJ (2009) 1.06
Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection. J Immunol (2008) 1.05
A systematic review of high quality diagnostic tests for Chagas disease. PLoS Negl Trop Dis (2012) 1.05
Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection. J Exp Med (2012) 1.04
Zika Virus Disrupts Neural Progenitor Development and Leads to Microcephaly in Mice. Cell Stem Cell (2016) 1.04
Tailoring deposition and morphology of discharge products towards high-rate and long-life lithium-oxygen batteries. Nat Commun (2013) 1.04
Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARγ/NF-κB pathway. Respir Res (2012) 1.04
Preclinical derivation and imaging of autologously transplanted canine induced pluripotent stem cells. J Biol Chem (2011) 1.04
Tetherin inhibits prototypic foamy virus release. Virol J (2011) 1.02
CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance. J Immunol (2010) 1.02
Cutting edge: dysfunctional CD8+ T cells reside in nonlymphoid tissues during chronic Trypanosoma cruzi infection. J Immunol (2003) 1.02
Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors. Clin Exp Pharmacol Physiol (2007) 1.01
miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α. Cancer Biol Ther (2015) 1.00
Monoacylglycerol acyltransferase-2 is a tetrameric enzyme that selectively heterodimerizes with diacylglycerol acyltransferase-1. J Biol Chem (2014) 0.99
Methodological advances in drug discovery for Chagas disease. Expert Opin Drug Discov (2011) 0.98
Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease. Acta Pharmacol Sin (2007) 0.98
On Tikhonov regularization for image reconstruction in parallel MRI. Conf Proc IEEE Eng Med Biol Soc (2004) 0.98
Microarray profiling of gene expression during trypomastigote to amastigote transition in Trypanosoma cruzi. Mol Biochem Parasitol (2003) 0.98
In situ fabrication of porous graphene electrodes for high-performance energy storage. ACS Nano (2013) 0.98
Epidemiological characteristics and meteorological factors of childhood Mycoplasma pneumoniae pneumonia in Hangzhou. World J Pediatr (2011) 0.96
Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine (2003) 0.96
Quercetin attenuates airway inflammation and mucus production induced by cigarette smoke in rats. Int Immunopharmacol (2012) 0.96
Toll-like receptor 4 relates to lipopolysaccharide-induced mucus hypersecretion in rat airway. Arch Med Res (2009) 0.96
Characterization of 19 novel cotton FLA genes and their expression profiling in fiber development and in response to phytohormones and salt stress. Physiol Plant (2008) 0.95
Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease. PLoS One (2012) 0.95
Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge. Infect Immun (2011) 0.94
Swainsonine activates mitochondria-mediated apoptotic pathway in human lung cancer A549 cells and retards the growth of lung cancer xenografts. Int J Biol Sci (2012) 0.94
Predicting marital satisfaction from self, partner, and couple characteristics: is it me, you, or us? J Pers (2008) 0.93
Doxycycline attenuates acrolein-induced mucin production, in part by inhibiting MMP-9. Eur J Pharmacol (2010) 0.93
Application of perceptual difference model on regularization techniques of parallel MR imaging. Magn Reson Imaging (2005) 0.92
Tracheal diverticula in infants: a report of three cases. Clin Imaging (2012) 0.92
MicroRNA regulation of lymphocyte tolerance and autoimmunity. J Clin Invest (2015) 0.92
Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens. Ann Hematol (2012) 0.91
TGF-beta regulates pathology but not tissue CD8+ T cell dysfunction during experimental Trypanosoma cruzi infection. Eur J Immunol (2007) 0.91
MicroRNAs regulate bone metabolism. J Bone Miner Metab (2013) 0.91
Synthesis of perovskite-based porous La(0.75)Sr(0.25)MnO3 nanotubes as a highly efficient electrocatalyst for rechargeable lithium-oxygen batteries. Angew Chem Int Ed Engl (2013) 0.90
A semi-quantitative GeLC-MS analysis of temporal proteome expression in the emerging nosocomial pathogen Ochrobactrum anthropi. Genome Biol (2007) 0.90
Limited role for CD4+ T-cell help in the initial priming of Trypanosoma cruzi-specific CD8+ T cells. Infect Immun (2006) 0.90
Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA. Expert Opin Drug Discov (2011) 0.90
Opposing roles for JNK and Aurora A in regulating the association of WDR62 with spindle microtubules. J Cell Sci (2015) 0.90
Caffeine-induced fetal rat over-exposure to maternal glucocorticoid and histone methylation of liver IGF-1 might cause skeletal growth retardation. Toxicol Lett (2012) 0.90
Ox-LDL-induced TGF-β1 production in human alveolar epithelial cells: involvement of the Ras/ERK/PLTP pathway. J Cell Physiol (2012) 0.89
Quercetin inhibits IL-1 beta-induced ICAM-1 expression in pulmonary epithelial cell line A549 through the MAPK pathways. Mol Biol Rep (2008) 0.89
Inducible nitric oxide synthase is not essential for control of Trypanosoma cruzi infection in mice. Infect Immun (2004) 0.89
Evidence for the role of vacuolar soluble pyrophosphatase and inorganic polyphosphate in Trypanosoma cruzi persistence. Mol Microbiol (2013) 0.89
Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients. Pharmacogenet Genomics (2012) 0.88
Cytochrome P450 2C8 ω3-long-chain polyunsaturated fatty acid metabolites increase mouse retinal pathologic neovascularization--brief report. Arterioscler Thromb Vasc Biol (2014) 0.88
Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant (2009) 0.88
Perpetual expression of PAMPs necessary for optimal immune control and clearance of a persistent pathogen. Nat Commun (2013) 0.88
Role of extracellular signal-regulated kinase 1/2 in cigarette smoke-induced mucus hypersecretion in a rat model. Chin Med J (Engl) (2011) 0.88